Jazz Pharmaceuticals (NASDAQ:JAZZ) PT Lowered to $120.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price reduced by Wells Fargo & Company from $140.00 to $120.00 in a research note issued to investors on Thursday, Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the specialty pharmaceutical company’s stock.

Several other equities research analysts have also recently issued reports on JAZZ. Robert W. Baird decreased their price objective on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an outperform rating for the company in a research report on Thursday. Needham & Company LLC dropped their price objective on Jazz Pharmaceuticals from $208.00 to $205.00 and set a buy rating on the stock in a report on Thursday. Cantor Fitzgerald reaffirmed an overweight rating and issued a $180.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, April 10th. UBS Group decreased their price target on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a neutral rating for the company in a research note on Tuesday, July 2nd. Finally, Morgan Stanley lowered their price objective on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an equal weight rating on the stock in a research report on Friday, July 12th. Four investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of Moderate Buy and a consensus target price of $175.20.

Jazz Pharmaceuticals Stock Down 1.7 %

JAZZ stock traded down $1.90 during mid-day trading on Thursday, reaching $112.48. The company had a trading volume of 164,127 shares, compared to its average volume of 682,503. The firm has a fifty day simple moving average of $107.68 and a 200 day simple moving average of $114.15. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.90 and a current ratio of 2.27. The company has a market capitalization of $7.09 billion, a price-to-earnings ratio of 23.40, a price-to-earnings-growth ratio of 1.70 and a beta of 0.58. Jazz Pharmaceuticals has a fifty-two week low of $99.06 and a fifty-two week high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share for the quarter, missing the consensus estimate of $3.53 by ($1.55). Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.89%. The firm had revenue of $901.98 million during the quarter, compared to analyst estimates of $938.99 million. Analysts forecast that Jazz Pharmaceuticals will post 15.31 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in shares of Jazz Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock worth $776,551,000 after purchasing an additional 84,941 shares during the period. LSV Asset Management boosted its holdings in Jazz Pharmaceuticals by 1.6% during the first quarter. LSV Asset Management now owns 2,380,858 shares of the specialty pharmaceutical company’s stock worth $286,703,000 after buying an additional 37,631 shares in the last quarter. Polaris Capital Management LLC grew its position in Jazz Pharmaceuticals by 13.0% during the first quarter. Polaris Capital Management LLC now owns 1,432,660 shares of the specialty pharmaceutical company’s stock worth $172,521,000 after buying an additional 165,200 shares during the period. Capital World Investors purchased a new position in Jazz Pharmaceuticals in the first quarter valued at about $171,943,000. Finally, Swedbank AB acquired a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter valued at approximately $106,936,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.